AGP Executive Report
Last update: 9 hours agoFDA Supply Watch: The FDA says it’s working with estradiol transdermal patch makers to boost availability after reports of difficulty getting products, noting supply has nearly doubled over the past year and demand rose after recent menopausal hormone therapy label changes. Breast Cancer Update: The FDA granted accelerated approval to camizestrant (Etcamah) for ESR1-mutated, HR+/HER2– advanced or metastatic breast cancer detected during first-line aromatase inhibitor plus CDK4/6 therapy, based on SERENA-6 results. Urology Care Shift: For muscle-invasive bladder cancer, FDA expanded approval of enfortumab vedotin plus pembrolizumab to cover cisplatin-eligible patients as cystectomy candidates, tightening the treatment pathway. Pediatric Obesity Trend: A new U.S. EHR analysis finds GLP-1 use among children ages 8–11 with obesity is still uncommon but surged since 2019, raising questions about selection and long-term safety. Mental Health Safety: A watchdog group compiled 57 regulatory warnings tied to psychotropic drug risks involving violence or aggression, urging patients and clinicians to review labeling closely. Health Policy: Iowa labor experts discussed unionization challenges amid weaker bargaining laws and corporate pressure, highlighting ongoing worker organizing efforts.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
